Diana Graus Porta
Publications by Year
Research Areas
Fibroblast Growth Factor Research, Kruppel-like factors research, Epigenetics and DNA Methylation, Metastasis and carcinoma case studies, Cancer, Hypoxia, and Metabolism
Most-Cited Works
- → In vivo antitumor activity of NVP-AEW541—A novel, potent, and selective inhibitor of the IGF-IR kinase(2004)536 cited
- → Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma(2016)532 cited
- → Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase(2011)487 cited
- → Conditional disruption of β1 integrin in Schwann cells impedes interactions with axons(2002)325 cited
- → Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer(2013)312 cited
- → Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations(2018)255 cited
- → Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets(2012)146 cited
- → FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer(2019)100 cited
- → A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097(2015)87 cited
- → Abstract CT326: Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors(2014)76 cited